The human record
The published human record for these two peptides is short enough to list in one table, and Table 1 does so. It is a record of what was measured, not a source of doses: neither molecule is an approved medicine, and this site does not turn study designs into instructions.
| Study | What the authors wrote |
|---|---|
| Teichman et al., 2006 J Clin Endocrinol Metab | No serious adverse reactions were reported. |
| Ionescu and Frohman, 2006 J Clin Endocrinol Metab | GH secretion was increased after CJC-1295 administration with preserved pulsatility. The frequency and magnitude of GH secretory pulses were unaltered. |
| Beck et al., 2014 International Journal of Colorectal Disease | There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses. |
CJC-1295: what the trials measured
The Teichman trials are the only controlled human data on CJC-1295: two randomized, double-blind, placebo-controlled studies in healthy adults, one of 28 days and one of 49 days. After one administration, mean plasma GH rose 2 to 10-fold and stayed up for 6 days or more; IGF-1 rose 1.5 to 3-fold and stayed up for 9 to 11 days. After repeated administration, IGF-1 remained above baseline for up to 28 days. The estimated half-life was 5.8 to 8.1 days [1].
Figure 6
What one CJC-1295 administration changed in the trial, and for how long (days)
- GH, single2-10×, 6+ days
- IGF-1, single1.5-3×, 9-11 days
- IGF-1, repeatedup to 28 days
In a second study, overnight sampling one week after a single administration showed trough GH 7.5-fold higher, mean GH 46 % higher and IGF-1 45 % higher, with no change in pulse frequency or amplitude [2]. The two CJC-1295 forms are compared in CJC-1295 DAC vs no DAC.
Ipamorelin: intravenous only
In healthy men infused intravenously, ipamorelin showed dose-proportional pharmacokinetics, a terminal half-life of 2 hours and a clearance of 0.078 l/h/kg; GH rose in a single episode that peaked at 0.67 hours and then fell back [3].
The two phase 2 trials that followed, run by Helsinn, tested whether a ghrelin-receptor agonist could shorten postoperative ileus after bowel surgery and did not measure GH. In 114 analysed patients, median time to a first tolerated meal was 25.3 hours against 32.6 with placebo, not significant (p = 0.15), and treatment-emergent adverse events were reported in 87.5 % of the ipamorelin group and 94.8 % of the placebo group [4]. The larger trial, 320 patients, is marked completed on the registry with no results posted [5].
No serious adverse reactions were reported.
The combination: no trial
No peer-reviewed study has administered CJC-1295 and ipamorelin together to people. The idea of pairing a GHRH analogue with a GHRP comes from Bowers' 1990 experiment in 18 men with two different molecules, GHRH(1-44) and GHRP-6, which released GH synergistically [6]. Any figure attached to the pair on a clinic page or a forum is therefore not from a trial, and this site does not add one.
